---
schema_version: "secwatch.filing_event.v1"
accession: "0001171843-23-004942"
form_type: "8-K"
ticker: "BCRX"
cik: "0000882796"
company_name: "BIOCRYST PHARMACEUTICALS INC"
filed_at: "2023-08-03T23:59:59+00:00"
generated_at: "2026-06-12T10:33:31.113210+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# BioCryst Q2 ORLADEYO rev $81M (+24% YoY); on track for FY $320M; GAAP EPS ($0.40)

## Summary
- ORLADEYO net revenue $81.0M in Q2 2023, up 24.2% YoY from $65.2M; total revenues $82.5M (+25.9% YoY).
- GAAP net loss $75.3M ($0.40/share) vs $58.9M ($0.32/share) in Q2 2022; includes $29M one-time debt extinguishment fee.
- Non-GAAP EPS ($0.24) after excluding the one-time fee; operating cash use $13.5M in Q2.
- Reaffirmed FY 2023 ORLADEYO revenue guidance of >=$320M; peak revenue target $1B.
- R&D day set for Nov 3, 2023 to introduce pipeline assets; BCX10013 trial enrollment in PNH expected by year-end.

## SEC filing metadata
- accession: 0001171843-23-004942
- form_type: 8-K
- ticker: BCRX
- cik: 0000882796
- company_name: BIOCRYST PHARMACEUTICALS INC
- filed_at: 2023-08-03T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/882796/000117184323004942/0001171843-23-004942-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/882796/000117184323004942/f8k_080323.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001171843-23-004942
- JSON: https://secwatch.observer/filing/0001171843-23-004942.json
- Plain text: https://secwatch.observer/filing/0001171843-23-004942.txt

## Key facts
- Earnings Releases
  BIOCRYST PHARMACEUTICALS INC reported the second quarter ended June 30, 2023 results: revenue $82.5 million, net income Net loss for the second quarter of 2023 was $75.3 million, or $0.40 per share, EPS $0.40 per share. Guidance raised.
  - Period: the second quarter ended June 30, 2023
  - Revenue: $82.5 million
  - Net income: Net loss for the second quarter of 2023 was $75.3 million, or $0.40 per share
  - EPS: $0.40 per share
  - Guidance: raised
  - Result: reported results
  source text: For the three months ended June 30, 2023, total revenues were $82.5 million, compared to $65.5 million in the second quarter of 2022 (+25.9 percent year-over-year (y-o-y)).
  evidence_url: https://www.sec.gov/Archives/edgar/data/882796/000117184323004942/0001171843-23-004942-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.